M ultiple trials have demonstrated that bivalirudin provides comparable efficacy to heparin plus glycoprotein IIb/ IIIa inhibitors (GPI) and improved safety with fewer bleeding complications. [1] [2] [3] [4] Bivalirudin is indicated for the treatment of acute coronary syndrome among patients intended for invasive management, including primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction, and is recommended by both the European Society of Cardiology (ESC) and American College of Cardiology Foundation/American Heart Association ST-segment-elevation myocardial infarction guidelines. 5,6 Evidence supporting bivalirudin in primary PCI stems from the Harmonizing Background-In European Ambulance Acute Coronary Syndrome Angiography (EUROMAX), bivalirudin improved 30-day clinical outcomes with reduced major bleeding compared with heparins plus optional glycoprotein IIb/IIIa inhibitors. We assessed whether choice of access site (radial or femoral) had an impact on 30-day outcomes and whether it interacted with the benefit of bivalirudin. Methods and Results-In EUROMAX, choice of arterial access was left to operator discretion. Overall, 47% of patients underwent radial and 53% femoral access. Baseline risk was higher in the femoral access group. Unadjusted proportions for the primary outcome (death or noncoronary artery bypass graft protocol major bleeding at 30 days) were lower with radial access, however, without differences in major or major plus minor bleeding proportions. After multivariable adjustment, ischemic outcomes were no longer different between access site groups, except for a lower risk of stroke in radial patients. Bivalirudin was associated with lower proportions of the primary outcome in both the radial (odds ratio, 0.58; 95% CI, 0.33-1.03; P=0.058) and the femoral groups (odds ratio, 0.59; 95% CI, 0.37-0.93; P=0.022; interaction P=0.97). Bleeding was significantly lower in the bivalirudin group both in the radial-and femoral-treated patients but no significant difference was observed in ischemic outcomes. In multivariable analysis, bivalirudin emerged as the only independent predictor of reduced major bleeding (odds ratio, 0.45; 95% CI, 0.27-0.74; P=0.002). Conclusions-In this prespecified analysis from EUROMAX, radial access was preferred in lower risk patients and did not improve clinical outcomes. Bivalirudin was associated with less bleeding irrespective of access site. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01087723.
Bivalirudin in TRI for Primary PCI
Outcomes with Revasulariation and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial that demonstrated lower proportions of bleeding, net adverse clinical events and a 46% reduction in cardiovascular mortality at 3 years compared with heparin plus GPI. 3, 7 The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trial again reported lower proportions of bleeding and net adverse clinical events with bivalirudin in the setting of contemporary European practice with frequent use of the radial approach and new P2Y 12 inhibitors and only optional use of GPI with heparin. 8 However, recently, the How Effective are Antithrombotic Therapies in Primary PCI (HEAT-PPCI) trial reported that in a center with predominant use of radial access, frequent use of new P2Y 12 inhibitors, and without routine GPI use, heparin reduced ischemic events compared with bivalirudin without any difference in bleeding. 9 The lack of a bleeding benefit with bivalirudin was attributed to both the radial approach and the lower doses of heparin without systematic use of GPI. A recent prespecified analysis from EUROMAX demonstrated that bleeding reductions with bivalirudin were observed even in the setting of low-dose heparin without GPI. 10 In the current prespecified analysis from EUROMAX, we investigated whether the selection of arterial access site had an impact on 30-day outcomes and whether radial access mitigated the bleeding reduction benefit of bivalirudin.
Methods

Study Design
The detailed EUROMAX study design has been previously published. 11 In brief, patients ≥18 years presenting with ST-segment-elevation acute coronary syndrome intended for primary PCI within 2 hours of first medical contact were randomized to bivalirudin or heparins with optional GPI. The study was approved by an Institutional Review Board and all patients provided initial abridged written or oral consent, which was then subsequently confirmed by a formal written informed consent.
Bivalirudin was started immediately on enrollment as a 0.75 mg/kg bolus followed by a 1.75 mg/kg per hour infusion until completion of the PCI. Post procedure, the infusion was reduced to 0.25 mg/kg per hour for at least 4 hours, with an option to continue the full PCI dose of 1.75 mg/kg per hour, per the protocol. Patients who did not undergo PCI and were medically managed could continue the bivalirudin infusion of 0.25 mg/kg per hour for ≤72 hours.
Either unfractionated heparin (at guideline-recommended doses of 100 IU/kg without GPI or 60 IU/kg with a GPI) or enoxaparin (bolus of 0.5 mg/kg) was allowed and also given immediately on enrollment. Patients in the control group received unfractionated heparin at a median dose of 61 IU/kg with GPI and 60 IU/kg without GPI.
The use and type of GPI was left to physician preference and was categorized as either routine when started before the index procedure (emergent angiography±PCI) or bailout when started during or after the procedure for the management of large thrombus burden or no reflow. All patients were also to receive aspirin and a P2Y 12 inhibitor as soon as was logistically feasible, according to ESC recommended dosing guidelines.
The choice of arterial access was not randomized and left to the operator's discretion.
Study Outcomes
The primary outcome of EUROMAX was the composite of death or noncoronary artery bypass graft (CABG) protocol major bleeding
WHAT IS KNOWN
• Radial access is increasingly adopted for primary percutaneous coronary intervention based on studies reporting improved outcomes including lower mortality.
• Radial access can significantly reduce bleeding primarily through reductions of access site bleeding.
• Bivalirudin reduces major bleeding compared with heparin and glycoprotein IIb/IIIa inhibitor, but it is unknown if these benefits persist when glycoprotein IIb/IIIa inhibitor are not routinely used and radial access is preferred.
WHAT THE STUDY ADDS
• When access site choice is left at the physician's discretion radial access is more frequently chosen for lower risk patients.
• The benefits of the radial approach may not be as pronounced in a contemporary pharmacological environment.
• Bivalirudin independently reduces major bleeding irrespective of access site choice or the use of glycoprotein IIb/IIIa inhibitor in primary percutaneous coronary intervention. N is the total number of patients treated either by radial or femoral access; and n is the number in the subgroup. CABG indicates coronary artery bypass graft; IQR, interquartile range; PCI, percutaneous coronary intervention; and PTCA, percutaneous transluminal coronary angioplasty.
*Defined as a diagnosis of hyperlipidemia or the use of a lipid-lowering therapy. †Other includes Austria, Czech Republic, Italy, Poland, and Slovenia. N is the total number of patients treated either by radial or femoral access; and n is the number in the subgroup. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; GPI, glycoprotein IIb/IIIa inhibitor; IQR, interquartile range; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis in Myocardial Infarction. Bivalirudin in TRI for Primary PCI at 30 days and the key secondary outcome was the composite of death, reinfarction, or non-CABG major bleeding. Other secondary outcomes included separate ischemic and bleeding outcomes, major adverse cardiac events (death, reinfarction, ischemia-driven revascularization, or stroke), net adverse clinical events (composite of major adverse cardiac events and non-CABG major bleeding) and individually each of the components of the primary and key secondary composite outcomes, ischemia-driven revascularization, and stent thrombosis (as defined by the Academic Research Consortium). Detailed definitions of the individual end points have been previously published. 11 All deaths, bleeding, reinfarction, ischemia-driven revascularization, stent thrombosis, and strokes were adjudicated by an independent, blinded Clinical Events Committee.
Statistical Analysis
The impact of access site on 30-day outcomes and its interaction with the antithrombotic strategy was a prespecified subgroup analysis in EUROMAX. 8, 11 Continuous variables are reported as medians and interquartile ranges. Categorical variables are reported as frequencies and percentages. The χ 2 test was used to perform the primary analysis of comparisons of event proportions or Fisher exact test in the case of sparse data. Interaction between access site and treatment was derived from a logistic regression. The log-rank test was used to compute the significance of the secondary analysis of the time-to-event data, and event rates were estimated using the Kaplan-Meier method with curves plotted through day 30. Multivariable logistic regression 
N is the total number of patients treated either by radial or femoral access; and n is the number in the subgroup. CABG indicates coronary artery bypass graft; CI, confidence intervals; GUSTO, Global Use of Streptokinase and t-PA for Occluded Arteries; IDR, ischemia-driven revascularization; MACE, major adverse cardiac events; N/A, not applicable; NACE, net adverse clinical events; and TIMI, Thrombolysis in Myocardial Infarction. Bivalirudin in TRI for Primary PCI was used to correct for baseline imbalances between groups and to determine independent predictors of major outcomes. A significance level of 0.15 was required for a variable to enter the model and a level of 0.10 was required for a variable to be maintained in the model. Variables in the logistic regression model included: age >65 years, sex, anemia, renal function, diabetes mellitus, hypertension, hyperlipidemia, smoker, prior myocardial infarction, PCI, or CABG; choice of P2Y 12 inhibition (clopidogrel versus newer agents); pre-PCI Thrombolysis in Myocardial Infarction flow (0/1 versus 2/3); single or multivessel disease; Killip class >I; access site (femoral versus radial); drug-eluting stents; and anticoagulant strategy: bivalirudin versus heparins plus optional GPI. Analyses were performed using SAS software, version 9.2.
Results
Patients
A total of 2218 patients were enrolled in the trial; 2198 were included in the intent-to-treat population and randomized to bivalirudin (N=1089) or heparins with optional GPI (N=1109). Access site data were available for 2152 patients; radial access was used in 47% of patients and femoral in 53%. As detailed in Table 1 , baseline risk appeared higher in the femoral access group because patients were older and more frequently female, with a history of CABG, with renal impairment, anemia, and Killip class >1. Procedural characteristics and study medications by access site are presented in Table 2 . Administration of a P2Y 12 inhibitor loading dose before angiography was more frequent in the radial group. Overall GPI use was similar, but their use was more commonly routine in the femoral group, whereas bailout proportions were higher in the radial group. CABG during hospitalization was more frequent in the femoral access group, whereas guidelinerecommended discharge medications were more frequently prescribed in the radial group.
Overall Study Outcomes
First, we evaluated unadjusted outcomes according to choice of access site. Proportions of the primary and key secondary composite outcome were both lower with radial access, but there was no difference in major or major plus minor bleeding, regardless of the definition used (protocol or Thrombolysis in Myocardial Infarction definitions; Table 3 ). After multivariable analysis, adjusted odds ratios for all outcomes were similar between the radial and femoral groups except for the risk of stroke, which was lower with radial access (Figure 1 ).
Next, we evaluated the impact of study treatments on bleeding proportions in the radial and femoral populations independently. Proportions of major bleeding were consistently lower with bivalirudin in the radial (odds ratio [OR], 0.54; 95% confidence interval [CI], 0.28-1.05; P=0.065) and femoral groups (OR, 0.35; 95% CI, 0.19-0.65; P=0.0005; P interaction=0.35; Tables 4 and 5 ). Proportions of the primary outcome were also consistently reduced by bivalirudin compared with heparins with optional GPI in the radial (OR, 0.58; 95% CI, 0.33-1.03; P=0.058) and femoral groups (OR, 0.59; 95% CI, 0.37-0.93; P=0.022; P interac-tion=0.97), a difference primarily driven by reduction in bleeding, as the proportions of death or major adverse cardiac events did not significantly differ between the 2 groups (Tables 4 and 5) . Time-to-event curves for the primary outcome and for major bleeding according to randomized treatment are presented individually for the radial and femoral groups (Figures 2 and 3) . Proportions for the key secondary outcome were also lower with bivalirudin compared with heparin with optional GPI in the femoral (OR, 0.72; 95% CI, 0.48-1.09; P=0.1210) and radial groups (OR, 0.72; 95% CI, 0.42-1.21; P=0.2104) and time-to-event curves are individually presented for both groups (Figures I and II in the Data Supplement).
Finally, logistic regression analysis was performed to identify independent predictors for major bleeding, with choice of access site forced into the model ( Table I in 
Study Outcomes According to GPI Use
Patients randomized to heparins were treated with either routine GPI (58.5%) or with heparins alone (41.5%) according to their institutional standard practice. Patients randomized to bivalirudin and to heparins who were not receiving routine GPI could receive bailout GPI for giant thrombus or no reflow during the index procedure. A prespecified analysis of outcomes according to the use of GPI has been recently published and demonstrated consistent bleeding reductions with bivalirudin irrespective of GPI use. 9 In the present analysis, unadjusted outcomes showed a consistent reduction in bleeding with bivalirudin regardless of GPI use in the heparins group in both radial and femoral patients (Tables II and III in the Data Supplement) . Specifically, protocol major bleeding proportions for the radial group were 2.7% for the bivalirudin arm, 4.3% for the heparins with routine GPI arm, and 5.7% for the heparins alone arm. For the femoral group, the percentages were 2.5%, 6.7%, and 7.2%, respectively. Because the use of routine GPI and choice of access N is the total number of patients treated either by radial or femoral access; and n is the number in the subgroup. CABG indicates coronary artery bypass graft; CI, confidence intervals; GPI, glycoprotein IIb/IIIa inhibitor; GUSTO, Global Use of Streptokinase and t-PA for Occluded Arteries; IDR, ischemia-driven revascularization; MACE, major adverse cardiac events; N/A, not applicable; NACE, net adverse clinical events; and TIMI, Thrombolysis in Myocardial Infarction. Bivalirudin in TRI for Primary PCI were postrandomization decisions, an adjusted comparison of major bleeding according to both access site and GPI use was performed (Figure 4 ). The reduction in bleeding proportions with bivalirudin was consistent regardless of the choice of access site or the use of GPI (interaction P=0.29 for routine GPI arm; P=0.53 for heparin alone arm).
Discussion
In this prespecified subgroup analysis from EUROMAX, radial access was favored among lower risk patients. After adjustment for baseline imbalances, 30-day outcomes (including major bleeding) were similar regardless of the access site, except for a lower risk for stroke observed in the radial subgroup. The bleeding reductions afforded by bivalirudin in the overall population were also present in both the femoral and radial subgroups and remained consistent even after accounting for the use of GPI. In a logistic regression model, bivalirudin was an independent predictor of reduced bleeding, whereas radial access was not.
Our analysis, based on a nonrandomized selection of access site, suggests that radial access may be favored among lower risk patients. Accordingly, unadjusted 30-day outcomes favored the radial group, but after adjustment for baseline imbalances, the differences in outcomes between the access site groups were no longer evident, with the exception of a lower risk for stroke in the radial group. The observation is interesting and may warrant further study, however, it may also represent a chance finding because it is not supported by recent literature. 12, 13 So, how can the results of the present analysis be interpreted in the context of multiple randomized trials demonstrating significant bleeding reductions with radial access? [14] [15] [16] [17] [18] Plausible explanations for the lack of difference in outcomes between femoral and radial access could include evolution in contemporary practice and trial-specific differences. First, patient selection for randomization into access site trials may inadvertently lead to a tendency to exclude patients with a higher risk for radial access failure, such as octogenarians, females, and patients with cardiogenic shock, thereby possibly magnifying the beneficial impact of radial access. Second, in the emergent setting of primary PCI, less attention may be placed in the technique of femoral artery puncture and in combination with the aggressive antithrombotic therapy (including frequent GPI use) that may lead to higher bleeding and vascular complication proportions. Third, early trials included low proportions of vascular closure devices and infrequent use of bivalirudin, 2 bleeding avoidance strategies that are being increasingly adopted in contemporary practice. In fact, contemporary data from a large registry suggest that the absolute risk difference between the radial and femoral approach for access-related major bleeding complications maybe much lower than previously reported and closer to only 0.3%. 19 It is important to note, however, that regardless of the debate for the presence or magnitude of the clinical benefits associated with the radial approach, there are unquestionable benefits in patient comfort and important economic implications associated with immediate ambulation and early hospital discharge. Reducing bleeding remains a valid objective when performing PCI and our results suggest that regardless of preferred access site or the use of a GPI, bivalirudin is still associated with reduced bleeding based on the ability of mitigating both access site and nonaccess site-related bleeding.
Limitations
The data presented derive from a prespecified but postrandomization analysis and the results should be considered as 
Access Site Heparin Comparison Odds Ratio (± CI) P-value
Radial
Heparin with routine GPI 0.56 (0.23, 1.32) 0.19
Heparin only (bailout GPI) 0.45 (0.21, 0.97) 0.04
Femoral
Heparin with routine GPI 0.31 (0.15, 0.66) 0.002
Heparin only (bailout GPI) 0.28 (0.11, 0.7) 0.007 0.1 1 10 Bivalirudin better H eparin better Figure 4 . Adjusted proportions of major bleeding according to access site and glycoprotein IIb/IIIa inhibitor (GPI) use. The adjusted odds ratios, 95% confidence intervals (CI), and P values for the comparison of bivalirudin vs heparin with or without routine GPI by access site are shown. Bivalirudin in TRI for Primary PCI AngioX (MATRIX) trial (NCT01433627) 20 will provide important data on the influence of both choice of access and choice of antithrombotic therapy on clinical outcomes after acute coronary syndrome. In the interim, the present results show that the bleeding benefit of bivalirudin is consistently observed regardless of the choice of arterial access.
Conclusions
In this prespecified subgroup analysis from the contemporary EUROMAX trial, radial access for primary PCI was more commonly preferred in lower risk patients. Adjusted clinical outcomes, including bleeding, were comparable between patients treated via radial or femoral access. Bivalirudin consistently and independently reduced the risk of bleeding irrespective of the choice of arterial access and the use of a GPI.
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